Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Reply to: "calcium channel blockers therapy and the risk of prostate cancer death".

Santala EEE, Rannikko A, Murtola TJ.

Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32745. [Epub ahead of print] No abstract available.

PMID:
31633796
2.

PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.

Ahlberg MS, Adami HO, Beckmann K, Bertilsson H, Bratt O, Cahill D, Egevad L, Garmo H, Holmberg L, Johansson E, Rannikko A, Van Hemelrijck M, Jäderling F, Wassberg C, Åberg UWN, Bill-Axelson A.

BMJ Open. 2019 Aug 22;9(8):e027860. doi: 10.1136/bmjopen-2018-027860.

3.

Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy.

Lintula S, Mirtti T, Rannikko A, Bützow A, Lempiäinen A, Stenman J, Stenman UH, Hotakainen K.

Scand J Clin Lab Invest. 2019 Oct;79(6):424-430. doi: 10.1080/00365513.2019.1639214. Epub 2019 Jul 11.

PMID:
31294620
4.

Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT.

Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1642-1651. doi: 10.1158/1055-9965.EPI-18-1358. Epub 2019 Jul 10.

PMID:
31292140
5.

Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.

Blom S, Erickson A, Östman A, Rannikko A, Mirtti T, Kallioniemi O, Pellinen T.

Prostate. 2019 Sep;79(13):1505-1513. doi: 10.1002/pros.23867. Epub 2019 Jul 3.

6.

Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J.

Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j.euo.2018.08.017. Epub 2018 Sep 13.

PMID:
31200849
7.

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.

Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ.

PLoS Med. 2019 Jun 3;16(6):e1002813. doi: 10.1371/journal.pmed.1002813. eCollection 2019 Jun.

8.

Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking.

Petas A, Erickson A, Santti H, Matikainen M, Mirtti T, Rannikko A.

J Robot Surg. 2019 May 25. doi: 10.1007/s11701-019-00974-7. [Epub ahead of print]

PMID:
31129776
9.

Patient Experience of Systematic Versus Fusion Prostate Biopsies.

Eineluoto JT, Järvinen P, Kilpeläinen T, Lahdensuo K, Kalalahti I, Sandeman K, Mirtti T, Rannikko A.

Eur Urol Oncol. 2018 Aug;1(3):202-207. doi: 10.1016/j.euo.2018.02.005. Epub 2018 May 15.

PMID:
31102622
10.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.

Erickson AM, Luzzago S, Semjonow A, Vasarainen H, Laajala TD, Musi G, de Cobelli O, Mirtti T, Rannikko A.

Eur Urol Oncol. 2018 Sep;1(4):268-275. doi: 10.1016/j.euo.2018.04.006. Epub 2018 May 15.

PMID:
31100247
11.

Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.

Joentausta RM, Rannikko A, Murtola TJ.

Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16.

PMID:
30652328
12.

SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.

Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O.

Scand J Urol. 2018 Oct - Dec;52(5-6):313-320. doi: 10.1080/21681805.2018.1520295. Epub 2018 Dec 26.

PMID:
30585526
13.

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium.

Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29.

PMID:
30385049
14.

Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy.

Björk JK, Ahonen I, Mirtti T, Erickson A, Rannikko A, Bützow A, Nordling S, Lundin J, Lundin M, Sistonen L, Nees M, Åkerfelt M.

Oncotarget. 2018 Jul 27;9(58):31200-31213. doi: 10.18632/oncotarget.25756. eCollection 2018 Jul 27.

15.

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.

Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R, Lundin J, Järvinen P, Nisen H, Taari K, Af Hällström TM, Rannikko A, Mirtti T, Kallioniemi O, Östling P.

Int J Cancer. 2019 Mar 15;144(6):1356-1366. doi: 10.1002/ijc.31815. Epub 2018 Nov 4.

PMID:
30125350
16.

Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study.

Santala EE, Rannikko A, Murtola TJ.

Int J Cancer. 2019 Feb 1;144(3):440-447. doi: 10.1002/ijc.31802. Epub 2018 Nov 5.

PMID:
30110124
17.

Editorial Comment.

Rannikko A.

J Urol. 2018 Nov;200(5):1034. doi: 10.1016/j.juro.2018.05.156. Epub 2018 Jul 26. No abstract available.

PMID:
30056062
18.

Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.

Drost FH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, van der Poel HG, Bangma CH, Roobol MJ; PRIAS study group.

Transl Androl Urol. 2018 Feb;7(1):98-105. doi: 10.21037/tau.2017.12.28.

19.

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators.

N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.

20.

Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.

Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström PJ.

BJU Int. 2018 Aug;122(2):203-210. doi: 10.1111/bju.14198. Epub 2018 Apr 6.

21.

Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.

Kalalahti I, Huotari K, Lahdensuo K, Tarkka E, Santti H, Rannikko A, Pätäri-Sampo A.

Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1055-1060. doi: 10.1007/s10096-018-3217-7. Epub 2018 Mar 2.

PMID:
29500572
22.

New prostate cancer grade grouping system predicts survival after radical prostatectomy.

Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13. No abstract available.

23.

Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.

Närhi K, Nagaraj AS, Parri E, Turkki R, van Duijn PW, Hemmes A, Lahtela J, Uotinen V, Mäyränpää MI, Salmenkivi K, Räsänen J, Linder N, Trapman J, Rannikko A, Kallioniemi O, Af Hällström TM, Lundin J, Sommergruber W, Anders S, Verschuren EW.

J Pathol. 2018 May;245(1):101-113. doi: 10.1002/path.5059. Epub 2018 Apr 2. Erratum in: J Pathol. 2019 Jan;247(1):147.

24.

ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.

Pellinen T, Blom S, Sánchez S, Välimäki K, Mpindi JP, Azegrouz H, Strippoli R, Nieto R, Vitón M, Palacios I, Turkki R, Wang Y, Sánchez-Alvarez M, Nordling S, Bützow A, Mirtti T, Rannikko A, Montoya MC, Kallioniemi O, Del Pozo MA.

Sci Rep. 2018 Feb 5;8(1):2338. doi: 10.1038/s41598-018-20161-2.

25.

Repeat multiparametric MRI in prostate cancer patients on active surveillance.

Eineluoto JT, Järvinen P, Kenttämies A, Kilpeläinen TP, Vasarainen H, Sandeman K, Erickson A, Mirtti T, Rannikko A.

PLoS One. 2017 Dec 27;12(12):e0189272. doi: 10.1371/journal.pone.0189272. eCollection 2017.

26.

Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort.

Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, Boström PJ.

Eur Urol Focus. 2019 May;5(3):443-448. doi: 10.1016/j.euf.2017.12.001. Epub 2017 Dec 20.

PMID:
29275146
27.

Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.

Puhka M, Takatalo M, Nordberg ME, Valkonen S, Nandania J, Aatonen M, Yliperttula M, Laitinen S, Velagapudi V, Mirtti T, Kallioniemi O, Rannikko A, Siljander PR, Af Hällström TM.

Theranostics. 2017 Aug 23;7(16):3824-3841. doi: 10.7150/thno.19890. eCollection 2017.

28.

A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL.

Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.

PMID:
28762124
29.

PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.

Lokman U, Erickson AM, Vasarainen H, Rannikko AS, Mirtti T.

Eur Urol Focus. 2018 Dec;4(6):867-873. doi: 10.1016/j.euf.2017.03.004. Epub 2017 Mar 22.

30.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review.

31.

KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine.

Puhka M, Nordberg ME, Valkonen S, Rannikko A, Kallioniemi O, Siljander P, Af Hällström TM.

Eur J Pharm Sci. 2017 Feb 15;98:30-39. doi: 10.1016/j.ejps.2016.10.021. Epub 2016 Oct 19.

PMID:
27771514
32.

Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force.

Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, Van den Bergh R, Van Poppel H, Valdagni R, Bellardita L.

Eur Urol. 2017 Feb;71(2):274-280. doi: 10.1016/j.eururo.2016.09.041. Epub 2016 Oct 6.

PMID:
27720532
33.

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, Nordling S, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Mod Pathol. 2016 Dec;29(12):1565-1574. doi: 10.1038/modpathol.2016.154. Epub 2016 Aug 26.

34.

Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Lahdensuo K, Rannikko A, Anttila VJ, Erickson A, Pätäri-Sampo A, Rautio M, Santti H, Tarkka E, Vaara M, Huotari K.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):417-422. doi: 10.1038/pcan.2016.36. Epub 2016 Aug 16.

PMID:
27526964
35.

Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries.

Fosså SD, Bengtsson T, Borre M, Ahlgren G, Rannikko A, Dahl AA.

Scand J Urol. 2016 Oct;50(5):330-7. doi: 10.1080/21681805.2016.1201859. Epub 2016 Jul 11.

PMID:
27398736
36.

Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.

Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I.

Eur Urol. 2017 Apr;71(4):648-655. doi: 10.1016/j.eururo.2016.06.011. Epub 2016 Jun 24.

PMID:
27349615
37.

A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.

Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ; PRIAS study group.

Eur Urol. 2016 Dec;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007. Epub 2016 Jun 19.

PMID:
27329565
38.

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM.

Eur Urol. 2017 Mar;71(3):319-327. doi: 10.1016/j.eururo.2016.04.019. Epub 2016 May 6.

39.

Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care.

Riikonen J, Kaipia A, Petas A, Horte A, Koskimäki J, Kähkönen E, Boström PJ, Paananen I, Kuisma J, Santti H, Matikainen M, Rannikko A.

Scand J Urol. 2016 Jun;50(3):149-54. doi: 10.3109/21681805.2016.1142471. Epub 2016 Feb 16.

PMID:
26881411
40.

Active surveillance for prostate cancer: a narrative review of clinical guidelines.

Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ; Movember GAP3 consortium.

Nat Rev Urol. 2016 Mar;13(3):151-67. doi: 10.1038/nrurol.2015.313. Epub 2016 Jan 27. Review.

PMID:
26813955
41.

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.

Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A.

BJU Int. 2016 Sep;118(3):366-71. doi: 10.1111/bju.13410. Epub 2016 Feb 12.

42.

The diagnostics of prostate cancer is changing.

Sandeman K, Rannikko A, Kenttämies A, Mirtti T.

Duodecim. 2016;132(24):2351-8.

PMID:
29199795
43.

[Magnetic resonance imaging of prostate cancer].

Kenttämies A, Rannikko A.

Duodecim. 2015;131(13-14):1233-44. Review. Finnish.

PMID:
26536720
44.

Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.

Bokhorst LP, Alberts AR, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Bangma CH, Roobol MJ; PRIAS study group.

Eur Urol. 2015 Nov;68(5):814-21. doi: 10.1016/j.eururo.2015.06.012. Epub 2015 Jun 29.

PMID:
26138043
45.

Effects of resistance training on testosterone metabolism in younger and older men.

Ahtiainen JP, Nyman K, Huhtaniemi I, Parviainen T, Helste M, Rannikko A, Kraemer WJ, Häkkinen K.

Exp Gerontol. 2015 Sep;69:148-58. doi: 10.1016/j.exger.2015.06.010. Epub 2015 Jun 14.

PMID:
26079649
46.

Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).

Vasarainen H, Salman J, Salminen H, Valdagni R, Pickles T, Bangma C, Roobol MJ, Rannikko A.

World J Urol. 2015 Nov;33(11):1735-40. doi: 10.1007/s00345-015-1542-3. Epub 2015 Mar 31.

PMID:
25822705
47.

Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review.

Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, Villers A, Hugosson J, Moore CM.

Eur Urol. 2015 Apr;67(4):627-36. doi: 10.1016/j.eururo.2014.10.050. Epub 2014 Nov 15. Review.

PMID:
25511988
48.

Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.

Saeed K, Östling P, Björkman M, Mirtti T, Alanen K, Vesterinen T, Sankila A, Lundin J, Lundin M, Rannikko A, Nordling S, Mpindi JP, Kohonen P, Iljin K, Kallioniemi O, Rantala JK.

Int J Cancer. 2015 Jun 1;136(11):2535-45. doi: 10.1002/ijc.29303. Epub 2014 Nov 20.

49.

Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy.

Lahdensuo K, Mirtti T, Petas A, Rannikko A.

Scand J Urol. 2015 Apr;49(2):90-6. doi: 10.3109/21681805.2014.936494. Epub 2014 Jul 16.

PMID:
25028807
50.

Randomly organized lipids and marginally stable proteins: a coupling of weak interactions to optimize membrane signaling.

Rice AM, Mahling R, Fealey ME, Rannikko A, Dunleavy K, Hendrickson T, Lohese KJ, Kruggel S, Heiling H, Harren D, Sutton RB, Pastor J, Hinderliter A.

Biochim Biophys Acta. 2014 Sep;1838(9):2331-40. doi: 10.1016/j.bbamem.2014.03.005. Epub 2014 Mar 21.

Supplemental Content

Loading ...
Support Center